Press release
Conagen Wins SynBioBeta Award for Non-GMO HMO and Human Lactoferrin
Bedford, Mass. (Sept. 29 2020) --- SynBioBeta’s (SBB) Synthetic Biology Global Conference awarded Conagen the “Best Product of the Year” for its human lactoferrin and non-GMO human milk oligosaccharide (HMO.)Human lactoferrin is a critical iron-binding compound for immunity and iron nutrition. HMOs are important nutritional compounds only found in human milk. The most abundant HMO in human milk is 2’-fucosyllactose (2’FL), and it is responsible for promoting good gut bacteria, strengthening the gut barrier function, and suppressing pathogens.
“Conagen is honored to accept this award from SynBioBeta for our human lactoferrin and non-GMO HMO infant formula ingredients, but we do not intend to stop there. We are dedicated to continuously improving infant health and nutrition by expanding our portfolio with many more innovative infant formula ingredients,” said VP of Innovation, Dr. Casey Lippmeier.
In addition to their human lactoferrin and non-GMO HMO and products, Conagen is the first company to commercialize an odorless and tasteless butyrate releaser, otherwise known as FBA. FBA delivers butyrate, a short-chain fatty acid that helps infants develop gut and immune systems for mitigating a number of pathologies, including common food allergies to cow’s milk (1). It is an important health postbiotic and probiotic molecule for building gut health and immunity.
While Conagen’s FBA has been licensed in the infant formula space, there are partnership opportunities still available in applications spanning food and beverage, medical nutrition, dietary supplements, and pharmaceuticals.
“Today we are announcing our third offering for infant formula fortification, a compound which delivers butyrate to the infant gut in a way which safely conveys its important, well-characterized post-biotic effects, while retaining the accepted flavor of formula for babies’ palates,” said Lippmeier.
References:
Canani, Roberto Berni, et al. "Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants." The ISME journal 10.3 (2016): 742-750.
###
Conagen
15 DeAngelo
Bedford, MA, 01730
USA
Contact: Ana Arakelian
ana.arakelian@conagen.com
About Conagen
Conagen is making the impossible possible. Our scientists and engineers use the latest synthetic biology tools to develop high-quality sustainable nature-based products through systems of manufacturing on a molecular level and fermentation basis. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. For more information, visit www.conagen.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Conagen Wins SynBioBeta Award for Non-GMO HMO and Human Lactoferrin here
News-ID: 2145405 • Views: …
More Releases for HMO
Human Milk Oligosaccharides (HMO) Market Share $332.6Million by 2028
According to a new report published by Allied Market Research, titled, "Human Milk Oligosaccharides (HMOs) Market by Type, Application, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2028,"the global human milk oligosaccharides (HMO) market size was valued at $125.9 million in 2020, and is estimated to reach $332.6 million by 2028, registering a CAGR of 14.1% from 2021 to 2028.
Get a Sample PDF Report to understand our report before…
HMO Letting Agent Offers Comprehensive Guide on Finding Ideal HMO Properties
Image: https://lh7-us.googleusercontent.com/docsz/AD_4nXdeRv4NIF32OiXWyCk_Lgr-98A3ijzyBNqao0HtbwwKuAho9YNawZy2S1kszKE2N-k57rQrpogntqzJs2e8E6rcg2-3TToSnnOTitaEQnVfVwBF2yWUymqyLN8z5cTcDB2LHdA5ZVXm9usRTJtfDvkJvjO8?key=7pbbAt0GXq4x8JdfD2bfWw
If you're considering investing in property, HMO (House in Multiple Occupation) properties might be profitable. These properties are rental units shared by three or more tenants who aren't from the same household. They offer high rental yields and cater to the growing demand for shared accommodation. Working with an HMO Management Agency [https://hmolettingagent.co.uk/hmo-management/] can streamline the process and ensure compliance with legal requirements. This article will guide you through…
Human Milk Oligosaccharides (HMO) Market Insights and Future Outlook
According to a new report published by Allied Market Research, titled, "Human Milk Oligosaccharides (HMOs) Market by Type, Application, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2028,"the global human milk oligosaccharides (HMO) market size was valued at $125.9 million in 2020, and is estimated to reach $332.6 million by 2028, registering a CAGR of 14.1% from 2021 to 2028.
📍𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐬 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬 @ https://www.alliedmarketresearch.com/request-sample/A12027
💡𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐎𝐟𝐟𝐞𝐫…
How Big is Human Milk Oligosaccharides (HMO) Market?
The Global Human Milk Oligosaccharides (HMO) Market was valued at USD 196.5 million in 2022 and is projected to witness lucrative growth by reaching up to USD 850.5 million by 2030. The market is growing at a CAGR of 20.1% during the forecast period 2024-2031.
A new Report by DataM Intelligence, titled "Human Milk Oligosaccharides (HMO) Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031,"" offers a comprehensive analysis…
Human Milk Oligosaccharides (HMO) Market Regional Analysis & Forecast
The global Human Milk Oligosaccharides Market is estimated to be valued at USD 199 million in 2022. It is projected to reach USD 556 million by 2027, recording a CAGR of 22.7% during the forecast period.
The global HMO market has been influenced by some of the macroeconomic and microeconomic factors witnessed in some key countries. This would prove strong enough to drive the market significantly in terms of value…
Global Human Milk Oligosaccharides (HMO) Market Research Report 2016
This report studies Human Milk Oligosaccharides (HMO) in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
Beghin Meiji (France)
Beneo-Orafti SA (Belgium)
Cargill, Inc. (US)
Cosucra Groupe Warcoing SA (Belgium)
Ingredion Incorporated (US)
Royal Cosun (The Netherlands)
Sensus (The Netherlands)
Yakult Pharmaceutical Industry Co., Ltd. (Japan)
Major Manufacturers of Prebiotic Food Products
Abbott Nutrition (US)
Clasado BioSciences…